GlycA, a novel pro-inflammatory glycoprotein biomarker is associated with mortality:results from the PREVEND study and meta-analysis by Gruppen, E G et al.
  
 University of Groningen
GlycA, a novel pro-inflammatory glycoprotein biomarker is associated with mortality
Gruppen, E G; Kunutsor, S K; Kieneker, L M; van der Vegt, B; Connelly, M A; de Bock, G H;
Gansevoort, R T; Bakker, S J L; Dullaart, R P F
Published in:
Journal of Internal Medicine
DOI:
10.1111/joim.12953
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Gruppen, E. G., Kunutsor, S. K., Kieneker, L. M., van der Vegt, B., Connelly, M. A., de Bock, G. H., ...
Dullaart, R. P. F. (2019). GlycA, a novel pro-inflammatory glycoprotein biomarker is associated with
mortality: results from the PREVEND study and meta-analysis. Journal of Internal Medicine.
https://doi.org/10.1111/joim.12953
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 13-11-2019
doi: 10.1111/joim.12953
GlycA, a novel pro-inflammatory glycoprotein biomarker is
associated with mortality: results from the PREVEND study
and meta-analysis
E. G. Gruppen1,2 , S. K. Kunutsor3,4 , L. M. Kieneker1, B. van der Vegt5, M. A. Connelly6, G. H. de Bock7, R. T.
Gansevoort1, S. J. L. Bakker1 & R. P. F. Dullaart2
From the 1Divisions of, Nephrology; 2Endocrinology, Department of Internal Medicine, University of Groningen, University Medical Center
Groningen, Groningen, The Netherlands; 3National Institute for Health Research Bristol Biomedical Research Centre, University Hospitals
Bristol NHS Foundation Trust and University of Bristol; 4Translational Health Sciences, Musculoskeletal Research Unit, Bristol Medical
School, Southmead Hospital, University of Bristol, Bristol, UK; 5Division of Pathology, Department of Pathology and Medical Biology,
University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; 6Laboratory Corporation of America Holdings
(LabCorp), Morrisville, NC, USA; and 7Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen,
The Netherlands
Abstract. Gruppen EG, Kunutsor SK, Kieneker LM,
van der Vegt B, Connelly MA, de Bock GH,
Gansevoort RT, Bakker SJL, Dullaart RPF. GlycA,
a novel pro-inflammatory glycoprotein biomarker
is associated with mortality: results from the
PREVEND study and meta-analysis. J Intern Med.
2019; https://doi.org/10.1111/joim.12953
Background. Chronic diseases are associated with an
inflammatory response. We determined the asso-
ciation of two inflammatory markers, GlycA and
high-sensitivity C-reactive protein (hsCRP), with
overall and cause-specific mortality in a cohort of
men and women.
Methods. Cox regression analyses were used to
examine associations of GlycA and hsCRP with
all-cause, cancer and cardiovascular mortality in
5526 subjects (PREVEND cohort; average follow-
up 12.6 years).
Results. GlycA was associated with all-cause mortal-
ity (n = 838), independent of clinical risk factors
and hsCRP (hazard ratio 1.43 [95% confidence
interval (CI): 1.09–1.87] for top versus bottom
quartiles). For hsCRP, the association with all-
cause mortality was nonsignificant after
adjustment for GlycA. GlycA and hsCRP were
associated with cancer mortality in men
(n = 248), but not in women (n = 132). Neither
GlycA nor hsCRP was independently associated
with cardiovascular mortality (n = 201). In a meta-
analysis of seven population-based studies,
including 8153 deaths, the pooled multivariable-
adjusted relative risk of GlycA for all-cause mor-
tality was 1.74 (95% CI: 1.40–2.17) for top versus
bottom quartiles. The association of GlycA with all-
cause mortality was somewhat stronger than that
of hsCRP. GlycA and hsCRP were not indepen-
dently associated with cardiovascular mortality.
The associations of GlycA and hsCRP with cancer
mortality were present in men, but not in women.
Conclusions. GlycA is significantly associated with all-
cause mortality. GlycA and hsCRP were each not
independently associated with cardiovascular mor-
tality. The association of GlycA and hsCRP with
cancer mortality appears to be driven by men.
Keywords: C-reactive protein, GlycA, glycoproteins,
inflammation, mortality, nuclear magnetic reso-
nance spectroscopyPA.
Introduction
Accumulating evidence shows that there may be a
link between systemic low-grade inflammation and
major adverse health issues. Numerous studies
have shown an association between low-grade
inflammation and lifestyle factors such as obesity
[1], exercise [2], smoking [3] and diet [4]. In
addition, enhanced low-grade inflammation may
play a role in the aetiology of chronic diseases such
as cardiovascular disease (CVD) [5], type 2 dia-
betes (T2D) [6] and cancer [7].
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GlycA and high-sensitivity C-reactive protein
(hsCRP) are both markers of low-grade systemic
inflammation. Whilst GlycA is a composite biomar-
ker that senses the glycosylation states of several of
the most abundant acute-phase proteins [8],
hsCRP is a single marker of low-grade systemic
inflammation. GlycA is determined using nuclear
magnetic resonance (NMR) spectroscopy; the sig-
nal comes from N-acetyl methyl groups mostly
bound to acute-phase proteins [mainly: a1-acid
glycoprotein (oromucosoid), haptoglobin, a1-antit-
rypsin, a1-antichymotrypsin and transferrin] [8].
GlycA and hsCRP were found to be rather strongly
correlated with each other [8–10], but hsCRP is not
highly glycosylated, thus it contributes negligibly
to the measured GlycA signal.
GlycA has been found to be associated with inci-
dent CVD events as well as with new onset T2D in
multiple large studies [9,11–15]. Interestingly, its
association with CVD and with incident T2D
remained present after adjustment for hsCRP,
suggesting that the association of GlycA with
adverse cardiometabolic outcomes is as at least
as strong as that with hsCRP. Of further interest,
GlycA has been shown to be associated with cancer
incidence in the Women’s Health Study (WHS) [16]
and with cancer-hospitalization and mortality in
the Multi-Ethnic Study of Atherosclerosis (MESA)
[11].
We have recently shown that higher levels of GlycA
were associated with reduced life expectancy [17].
Furthermore, the association of GlycA with all-
cause mortality has been evaluated in a number of
studies. GlycA was associated with all-cause mor-
tality in high-risk populations of subjects with
established CVD or with several cardiovascular
risk factors [18–20]. Comparable results on GlycA
and all-cause mortality were found in general
population-based studies [11,21]. However, pub-
lished studies on GlycA and all-cause mortality
showed effect sizes ranging from 1.30 to 2.40. The
current study will investigate how the variability in
effect size might be explained. Further, limited data
are available with regard to GlycA and cause-
specific mortality.
Hence, the aims of the current study were (i) to
examine the associations of GlycA and hsCRP with
all-cause, CVD and cancer mortality in the Preven-
tion of Renal and Vascular End-Stage Disease
(PREVEND) cohort, a general predominantly Cau-
casian population of both men and women and (ii)
to report on a meta-analysis of published evidence
on the association of GlycA with all-cause
mortality.
Subjects and methods
Study design and population
The Prevention of Renal and Vascular End-Stage
Disease (PREVEND) study was designed to inves-
tigate the natural course of increased levels of
urinary albumin excretion and its relation to renal
and CVD in a large cohort drawn from the general
population. In short, in the period from 1997 to
1998, all inhabitants of the city of Groningen (The
Netherlands) aged 28–75 years were asked to send
in a morning urine sample and to fill out a short
questionnaire. Pregnant women and subjects with
type 1 diabetes mellitus were excluded. Urinary
albumin concentration was assessed in 40 856
(47.8%) responders. Subjects with a urinary albu-
min concentration of ≥10 mg L1 (n = 7768) were
invited to participate, of whom 6000 agreed. Fur-
thermore, 3394 randomly selected subjects with a
urinary albumin concentration <10 mg L1 were
invited and 2592 agreed to participate. These 8592
individuals constitute the actual PREVEND cohort.
For the current study, data were used from the
second screening round (2001–2003) in which
6894 subjects participated. GlycA and hsCRP were
measured in 5526 subjects of the second screening
round (Figure S1). The PREVEND study has been
approved by the medical ethics committee of the
University Medical Center Groningen, The Nether-
lands, and was conducted in accordance with the
guidelines of the Declaration of Helsinki. All par-
ticipants gave written informed consent.
Mortality data
The cause of death was obtained by linking the
number of the death certificate to the primary
cause of death as coded by a physician from the
Dutch Central Bureau of Statistics (CBS). Causes
of death were coded according to the 10th revision
of the International Classification of Diseases.
Survival time for the participants was defined as
the period from the date of blood collection of the
participant at the second screening round to the
date of death from any cause or January first 2017,
until which date information about specific causes
of death follow-up information was available. If a
person had moved to an unknown destination, the
date on which the person was dropped from the
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municipal registry was used as the census date.
Cardiovascular mortality was defined as a cardio-
vascular event leading to or directly causing death.
Qualifying cardiovascular events were ICD-10
codes I10-I99, which include myocardial infarc-
tion, stroke, abdominal aortic aneurysm, pul-
monary embolism, arrhythmias, myocarditis,
cardiomyopathy, cardiac arrest, heart failure, cere-
brovascular diseases and intraoperative and post-
procedural complications and disorders of
circulatory system. Cancer mortality was defined
as death due to any type of malignancy (ICD-10
codes C00–C97).
Data collection
The procedures at each examination in the PRE-
VEND study have been described in detail previ-
ously [22]. In short, before the outpatient clinic
visit, all participants completed a questionnaire
regarding demographics, cancer, cardiovascular
and renal disease history, smoking habits, alcohol
consumption and medication use. Cancer inci-
dence was established by computerized record
linkage with the nationwide network and registry
of histo- and cytopathology in the Netherlands
(PALGA: Dutch Pathology Registry) [23]. A history
of cancer was defined as any type of malignancy,
indicated by the patient in the questionnaire or
obtained by PALGA.
Information on medication use (including oral
contraceptive use and hormone replacement ther-
apy) was combined with information from a phar-
macy-dispensing registry, which has complete
information on drug usage of >95% of subjects in
the PREVEND study. Body mass index (BMI) was
calculated as weight (kg) divided by height squared
(m). Smoking status was categorized as never,
former and current. Alcohol intake was categorized
as <10 g or ≥10 g per day. T2D was defined as a
fasting serum glucose level >7.0 mmol L1, a non-
fasting plasma glucose level >11.1 mmol L1, self-
report of a physician diagnosis or the use of
glucose-lowering drugs, retrieved from a central
pharmacy registry. Estimated glomerular filtration
rate (eGFR) was calculated using the combined
creatinine–cystatin C-based Chronic Kidney Dis-
ease Epidemiology Collaboration equation [24].
Laboratory measurements
Plasma samples were sent frozen to LipoScience/
LabCorp (Morrisville, NC, USA) for testing on the
Vantera Clinical Analyzer. NMR LipoProfile Test
spectra were collected and GlycA values were quan-
tified as previously described [8,14,25]. In short, the
GlycA NMR signal comes from the N-acetyl methyl
group protons of the N-acetylglucosamine moieties
located on the bi-, tri- and tetra-antennary branches
of plasma glycoproteins, mainly a1-acid glycoprotein,
haptoglobin, a1-antitrypsin, a1-antichymotrypsin
and transferrin. The coefficients of variation (CVs)
for the GlycA assay ranged from 1.3% to 2.3%.
hsCRP was measured by nephelometry with a
threshold of 0.18 mg L1 (BNII; Dade Behring, Mar-
burg, Germany). Plasma glucose was measured
using standard laboratory protocols [26]. Serum
total cholesterol was assayed on an automatic anal-
yser type MEGA (Merck, Darmstadt, Germany) using
the CHOD-PAP-method. Measurement of serum cre-
atinine was performed by an enzymatic method on a
Roche Modular analyzer (Roche Diagnostics, Man-
nheim, Germany). Serum cystatin C concentrations
were measured by Gentian Cystatin C Immunoassay
(Gentian AS, Moss, Norway) on a Modular analyzer
(Roche Diagnostics). Urinary albumin concentration
was measured by nephelometry with a threshold of
2.3 mg L1, and intra- and inter-assay CVs of 2.2%
and 2.6%, respectively (Dade Behring Diagnostic,
Marburg, Germany).
Statistical analysis
SPSS (version 22.0; SPSS Inc. Armonk, NY: IBM
Corp) and STATA version 13.1 (StataCorp, College
Station, TX: StataCorp LP) were used for data
analysis. Results are presented as mean  SD,
median (interquartile range) and percentages.
Skewed data were normalized by natural logarith-
mic (Loge) transformation before analyses, which
was the case for urinary albumin excretion (UAE)
and hsCRP. Baseline characteristics were calcu-
lated across sex-stratified quartiles of GlycA. P-
values across quartiles of GlycA were determined
by linear regression for continuous variables or
chi-square test for categorical variables. To study
the association of GlycA and hsCRP with mortality,
we fitted Cox proportional hazard models to the
data. Tests of trend across quartiles were con-
ducted by assigning the median value for each
quartile as its value and treating this as a contin-
uous variable. Results are summarized by hazard
ratios (HRs), with 95% confidence intervals. Possi-
ble effect modification was explored by including
the interaction terms between GlycA or hsCRP and
age, sex or smoking in the multivariable-adjusted
models. Interaction terms were considered to be
GlycA and mortality / E. G. Gruppen et al.
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statistically significant at two-sided P-values <0.10
[27]. Otherwise, the levels of significance were set
at two-sided P-values <0.05.
Meta-analysis of published studies
Studies that determined the association between
GlycA and all-cause mortality, published in full
text before 17 December 2018 (date last searched),
were identified through electronic searches not
limited to the English language using MEDLINE
and EMBASE. Reference lists from included arti-
cles were scanned as well. Summary measures
were presented as relative risks (RR) with 95% CI
intervals and were pooled using a random effects
model to minimize the effect of between-study
heterogeneity. We assessed heterogeneity using
the Cochrane chi-square statistic and the I2 statis-
tic.
Results
Table 1 shows the baseline characteristics accord-
ing to sex-stratified quartiles of GlycA. The mean
age of the subjects was 53.6  12.1 years at base-
line and 52.4% were women. Mean GlycA was
352  62 µmol L1 and median [IQR] hsCRP was
1.36 [0.62–3.08] mg L1. BMI, blood pressure,
glucose, total cholesterol, triglycerides, hsCRP
and UAE increased, whereas HDL cholesterol and
eGFR decreased when GlycA levels were higher.
Subjects with elevated GlycA were more likely to
have comorbid conditions such as hypertension,
CVD history, cancer history and T2D.
All-cause mortality
During an average follow-up of 12.6 years, 838
deaths were recorded. Associations of GlycA and
hsCRP with all-cause mortality are shown in
Table 2. GlycA was significantly associated with
all-cause mortality in a crude model, as well as
after adjustment for age, sex, BMI, alcohol con-
sumption and smoking status. Further adjustment
for T2D, blood pressure, use of lipid-lowering
drugs, anti-hypertensive medication use and lipids
did not substantially change the hazard associated
with GlycA. Results remained essentially the same
after further adjustment for CVD and cancer his-
tory (model 4) and renal function (model 5). Of
note, the P for trend was still significant after
adjustment for hsCRP. Results for hsCRP were
comparable to those for GlycA. However, after
adjustment for GlycA, the P for trend was no longer
significant. In addition, there were no statistically
significant interactions between GlycA or hsCRP
and age, sex or smoking on outcome [interactions:
P > 0.10 for all].
Cardiovascular mortality
During the follow-up period, 201 subjects died due
to CVD events (Table 3). GlycA was significantly
associated with CVD mortality in a crude model as
well as after adjustment for age, sex, BMI, alcohol
intake and smoking status. The association was
attenuated after adjustment for T2D, systolic blood
pressure, lipid-lowering drugs and anti-hyperten-
sive medication (model 2). In addition, statistical
significance was lost after adjustment for lipid
levels. This was also true for the analyses with
hsCRP as independent variable. There were no
significant interactions for each marker with age,
sex or smoking with CVD mortality.
Cancer mortality
In total, 380 participants died due to malignancies
(248 men and 132 women). Table 4 shows the
associations of GlycA and hsCRP with cancer
mortality. GlycA was associated with cancer mor-
tality in analyses adjusted for clinical covariates,
lipids and renal function. After additional adjust-
ment for hsCRP, the P for trend remained statically
significant. Results for hsCRP were comparable to
those for GlycA; however, in the final model, when
adjusted for GlycA, the P for trend was no longer
significant.
There was a significant interaction between hsCRP
and sex with cancer mortality (P for interaction
0.002, tested in a model with age and sex).
Table S1 shows the sex-stratified analysis of
hsCRP with cancer mortality. hsCRP was signifi-
cantly associated with cancer mortality in men but
not in women. The interaction term between GlycA
and sex was also significant in a model with age
and sex (P for interaction 0.045). In sex-stratified
analyses, GlycA was found to be significantly
associated with cancer mortality in men but not
in women (Table S2).
Exploratory analyses between GlycA and hsCRP
with lung cancer mortality (57 deaths) are pre-
sented in Table S3. GlycA was associated with lung
cancer mortality in a crude model as well as after
multivariable adjustments for clinical variables
and hsCRP. The association between hsCRP and
GlycA and mortality / E. G. Gruppen et al.
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Table 1 Baseline characteristics according to sex-stratified quartiles of GlycA concentrations in 5526 participants of the
PREVEND study
Quartiles of GlycA, µmol L1
1♂ ≤304♀ ≤313 2♂ 304–388♀313–352 3♂339–382♀ 353–394 4♂ >382♀ >394 P-value
Participants, n 1387 1386 1373 1380
Age, years 49.1  10.8 53.2  12.0 55.4  12.2 56.8  12.1 <0.001
Female, n (%) 732 (52.8) 718 (51.8) 720 (52.4) 723 (52.4) 0.99
BMI, kg m2 24.7  3.4 26.2  3.7 27.3  4.1 28.3  4.9 <0.001
Smoking, n (%)
Never 541 (39.0) 437 (31.5) 335 (24.4) 311 (22.5) <0.001
Former 588 (42.4) 611 (44.0) 610 (44.4) 539 (39.1)
Current 242 (17.4) 322 (23.2) 412 (30.0) 513 (37.2)
Alcohol intake, n (%)
<10 g d1 1339 (96.5) 1318 (95.1) 1297 (94.5) 1295 (93.8) <0.001
>10 g d1 37 (2.7) 55 (4.0) 65 (4.7) 71 (5.1)
Hypertension, n (%) 229 (16.5) 417 (30.1) 548 (39.9) 652 (47.2) <0.001
DBP, mm Hg 70.4  8.7 72.6  8.8 74.0  8.9 74.7  8.9 <0.001
SBP, mm Hg 119.0  15.7 124.5  18.2 128.5  19.7 131.3  19.6 <0.001
History of CVD 35 (2.5) 81 (5.8) 98 (7.1) 135 (9.8) <0.001
History of cancer 26 (1.9) 27 (1.9) 34 (2.5) 45 (3.3) 0.011
History of T2D, n (%) 34 (2.0) 69 (4.1) 134 (8.0) 182 (11.0) <0.001
Lipid-lowering drug
use, n (%)




135 (9.7) 264 (19.0) 372 (27.1) 459 (33.3) <0.001
Use of glucose-
lowering drugs, n (%)
8 (0.8) 28 (2.0) 59 (4.3) 80 (5.8) <0.001
hsCRP, mg L1 0.53 [0.27–0.99] 1.00 [0.57–1.78] 1.78 [0.98–3.25] 3.80 [1.96–7.30] <0.001
Glucose, mmol L1 4.7  0.9 4.9  0.9 5.1  1.2 5.3  1.5 <0.001
Total cholesterol,
mmol L1
5.2  1.0 5.4  1.0 5.5  1.1 5.6  1.1 <0.001
HDL cholesterol,
mmol L1
1.3  0.3 1.3  0.3 1.2  0.3 1.2  0.3 <0.001
Triglycerides,
mmol L1
0.85 [0.64–1.18] 1.05 [0.79–1.44] 1.24 [0.90–1.72] 1.39 [1.03–1.87] <0.001
eGFR (ml/min per
1.73 m2)
90.9  15.6 85.9  17.4 83.4  17.6 80.3  19.7 <0.001
UAE, mg/24 h 7.2 [5.7–10.4] 7.8 [5.8–12.3] 8.5 [6.1–14.4] 9.5 [6.3–20.6] <0.001
Data are expressed as mean  SD, median [IQR] or proportion n (%). P-values are calculated by linear regression or chi-
squared analysis.
BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFRcrea-cysC, estimated glomerular
filtration rate based on creatinine–cystatin C equation; HDL cholesterol, high-density lipoprotein cholesterol; hsCRP;
high-sensitive C-reactive protein; LDL cholesterol, low-density cholesterol; PREVEND, Prevention of Renal and Vascular
End-stage Disease; SBP, systolic blood pressure; UAE, urinary albumin excretion.
GlycA and mortality / E. G. Gruppen et al.
ª 2019 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine 5
Journal of Internal Medicine
lung cancer mortality was no longer significant
after adjustment for age, sex, BMI, alcohol intake
and smoking status (model 1). Exploratory analy-
ses between GlycA and hsCRP with death attribu-
table to gastrointestinal cancer (56 deaths) are
displayed in Table S4. After multivariable adjust-
ment, GlycA but not hsCRP was significantly
associated with gastrointestinal cancer.
Meta-analysis of published studies
We identified six population-based prospective
cohort studies that had reported associations
between circulating GlycA and all-cause mortality
risk (Table 5). Including the current study, the
pooled analysis involved seven studies comprising
63 180 participants and 8153 all-cause mortality
Table 2 Association between GlycA and hsCRP levels and all-cause mortality in 5526 participants (838 deaths) of the
PREVEND study




Participants (n) 1362 1395 1363 1406
Range, µmol L1 <309 ≥309 ≥346 ≥388
No. of deaths (%) 101 (7.4) 180 (12.9) 228 (16.7) 329 (23.4)
Crude Ref. 1.77 [1..39–2.26] <0.001 2.34 [1.86–2.96] <0.001 3.37 [2.70–4.22] <0.001 <0.001
Model 1 Ref. 1.11 [0.87–1.42] 0.42 1.37 [1.08–1.74] 0.01 1.78 [1.41–2.25] <0.001 <0.001
Model 2 Ref. 1.04 [0.81–1.33] 0.75 1.23 [0.96–1.56] 0.10 1.56 [1.23–1.98] <0.001 <0.001
Model 3 Ref. 1.085 [0.84–1.39] 0.55 1.26 [0.99–1.62] 0.06 1.65 [1.30–2.10] <0.001 <0.001
Model 4 Ref. 1.07 [0.84–1.38] 0.57 1.25 [0.98–1.60] 0.08 1.58 [1.24–2.02] <0.001 <0.001
Model 5 Ref. 1.08 [0.84–1.39] 0.54 1.24 [0.97–1.58] 0.09 1.51[1.19–1.93] 0.001 <0.001
Model 6 Ref. 1.07 [0.83–1.37] 0.61 1.20 [0.93–1.55] 0.17 1.43[1.09–1.87] 0.009 0.002
hsCRP
Participants (n) 1373 1388 1384 1381
Range, mg L1 <0.62 ≥0.62 ≥1.36 ≥3.08
No. of deaths(%) 107 (7.8) 165 (11.9) 247 (17.8) 319 (23.1)
Crude Ref. 1.53 [1.20–1.95] 0.001 2.37 [1.89–2.97] <0.001 3.16 [2.54–3.93] <0.001 <0.001
Model 1 Ref. 0.93 [0.73–1.19] 0.57 1.24 [0.98–1.57] 0.08 1.53 [1.22–1.93] <0.001 <0.001
Model 2 Ref. 0.95 [0.74–1.21] 0.66 1.19 [0.94–1.51] 0.14 1.42 [1.13–1.80] 0.003 <0.001
Model 3 Ref. 0.94 [0.73–1.20] 0.60 1.19 [0.93–1.51] 0.17 1.36 [1.07–1.73] 0.011 0.01
Model 33 Ref. 0.95 [0.74–1.22] 0.69 1.22 [0.96–1.55] 0.10 1.45 [1.14–1.83] 0.002 <0.001
Model 4 Ref. 0.95 [0.74–1.22] 0.69 1.22 [0.96–1.55] 0.10 1.45 [1.14–1.83] 0.002 <0.001
Model 5 Ref. 0.93 [0.72–1.19] 0.56 1.16 [0.91–1.47] 0.24 1.27 [1.00–1.62] 0.052 0.005
Model 6 Ref. 0.91 [0.71–1.16] 0.44 1.10 [0.86–1.41] 0.44 1.16 [0.88–1.51] 0.29 0.09
Hazard ratios were derived from Cox proportional hazards regression models.
Model 1: crude model + age, sex, BMI, alcohol intake (<10 g d1 or >10 g d1) and smoking status (never, former current).
Model 2: model 1 + diabetes, systolic blood pressure, lipid-lowering drugs and anti-hypertensive medications.
Model 3: model 2 + total cholesterol, HDL cholesterol and triglycerides.
Model 4: Model 3 + history of CVD and history of cancer.
Model 5: Model 4 + eGFRcreatinine cystatin C and UAE.
Model 6: Model 5 + hsCRP (for GlycA analyses) + GlycA (for hsCRP analyses).
Triglycerides, UAE and hsCRP were log transformed when used as a continuous variable in the analyses.
Abbreviations: BMI, body mass index; HDL cholesterol, high-density lipoprotein cholesterol; CVD, cardiovascular disease;
hsCRP, high–sensitivity C-reactive protein; UAE, urinary albumin excretion; PREVEND, Prevention of Renal and Vascular
End-stage Disease.
aTests of trend across increasing quartiles were conducted by assigning the median for each quartile as its value and
treating this as a continuous variable.
Values in bold are statistically significant (P<0.05).
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events. The pooled random effects multivariable-
adjusted RR for all-cause mortality when compar-
ing the top versus bottom quartiles of GlycA levels
was 1.74 (95% CI: 1.40–2.17). Significant hetero-
geneity was noted (I2 = 88%, 95% CI: 78–94;
P < 0.001; Fig. 1). When studies with high CVD
risk populations were excluded [18–20], the RR for
all-cause mortality comparing extreme quartiles of
GlycA was 1.37 (95% CI: 1.24–1.52). Heterogeneity
was reduced to nonsignificance (I2 = 8%, 95% CI:
0–86; P = 0.354). On exclusion of the study which
comprised of only women, the RR for all-cause
mortality comparing extreme quartiles of GlycA
was 1.84 (95% CI: 1.52–2.23).
Table 3 Association between GlycA and hsCRP levels and cardiovascular mortality in 5526 participants (201 deaths) of the
PREVEND study




Participants (n) 1362 1395 1363 1406
Range, µmol L1 <309 ≥309 ≥346 ≥388
No. of deaths (%) 21 (1.5) 47 (3.4) 51 (3.7) 82 (5.8)
Crude Ref. 2.23 [1.33–3.73] 0.002 2.53 [1.52–4.20] <0.001 4.05 [2.51–6.55] <0.001 <0.001
Model 1 Ref. 1.24 [0.74–2.09] 0.41 1.25 [0.74–2.09] 0.41 1.78 [1.09–2.93] 0.02 0.008
Model 2 Ref. 1.08 [0.64–1.81] 0.78 0.96 [0.57–1.62] 0.88 1.32 [0.80–2.19] 0.28 0.15
Model 3 Ref. 1.13 [0.66–1.93] 0.65 0.98 [0.57–1.67] 0.93 1.39 [0.83–2.34] 0.21 0.13
Model 4 Ref. 1.08 [0.63–1.84] 0.79 0.93 [0.54–1.60] 0.80 1.26 [0.75–2.13] 0.39 0.26
Model 5 Ref. 1.06 [0.62–1.81] 0.83 0.90 [0.53–1.55] 0.72 1.14 [0.67–1.93] 0.64 0.56
Model 6 Ref. 1.04 [0.61–1.78] 0.89 0.86 [0.49–1.50] 0.60 1.05 [0.59–1.85] 0.88 0.85
hsCRP
Participants (n) 1373 1388 1384 1381
Range, mg L1 <0.62 ≥0.62 ≥1.36 ≥3.08
No. of deaths (%) 29 (2.1) 33 (2.4) 60 (4.3) 79 (5.7)
Crude Ref. 1.13 [0.69–1.86] 0.63 2.12 [1.36–3.31] 0.001 2.89 [1.89–4.42] <0.001 <0.001
Model 1 Ref. 0.60 [0.36–0.99] 0.045 0.93 [0.58–1.47] 0.75 1.16 [0.74–1.81] 0.53 0.019
Model 2 Ref. 0.59 [0.36–0.98] 0.041 0.85 [0.54–1.34] 0.48 0.97 [0.62–1.53] 0.91 0.16
Model 3 Ref. 0.59 [0.35–0.98] 0.042 0.88 [0.55–1.40] 0.59 1.01 [0.64–1.61] 0.97 0.12
Model 4 Ref. 0.58 [0.35–0.97] 0.037 0.83 [0.52–1.34] 0.45 0.90 [0.56–1.44] 0.65 0.34
Model 5 Ref. 0.54 [0.32–0.91] 0.02 0.78 [0.48–1.25] 0.30 0.77 [0.47–1.25] 0.28 0.73
Model 6 Ref. 0.54 [0.32–0.91] 0.02 0.78 [0.48–1.26] 0.30 0.76 [0.45–1.30] 0.32 0.73
Hazard ratios were derived from Cox proportional hazards regression models.
Model 1: crude model + age, sex, BMI, alcohol intake (<10 g d1 or >10 g d1) and smoking status (never, former current).
Model 2: model 1 + diabetes, systolic blood pressure, lipid-lowering drugs and anti-hypertensive medications.
Model 3: model 2 + total cholesterol, HDL cholesterol and triglycerides.
Model 4: Model 3 + history of CVD and history of cancer.
Model 5: Model 4 + eGFRcreatinine cystatin C and UAE.
Model 6: Model 5 + hsCRP (for GlycA analyses) + GlycA (for hsCRP analyses).
Triglycerides, UAE and hsCRP were log transformed when used as a continuous variable in the analyses.
BMI, body mass index; HDL cholesterol, high-density lipoprotein cholesterol; CVD, cardiovascular disease; hsCRP, high–
sensitivity C-reactive protein; UAE, urinary albumin excretion; PREVEND, Prevention of Renal and Vascular End-stage
Disease.
aTests of trend across increasing quartiles were conducted by assigning the median for each quartile as its value and
treating this as a continuous variable.
Values in bold are statistically significant (P<0.05).
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Discussion
The present study demonstrates a significant
association of GlycA with all-cause mortality, inde-
pendent of established risk factors and potential
confounders. Our pooled finding from the meta-
analysis including 63 180 participants and 8153
deaths reinforces the validity and generalizability
of the findings. The observed heterogeneity
amongst these studies was explained by three
studies reporting on high-risk populations. The
positive association of hsCRP with all-cause mor-
tality was attenuated to nonsignificance after
adjustment for GlycA. GlycA and hsCRP were each
not independently associated with cardiovascular
mortality. In addition, sex-stratified analyses
Table 4 Association between GlycA and hsCRP levels and cancer mortality in 5526 participants (380 events) of the PREVEND
study




Participants (n) 1362 1395 1363 1406
Range, µmol L1 <309 ≥309 ≥346 ≥388
No. of deaths (%) 46 (3.4) 80 (5.7) 114 (8.4) 140 (10.0)
Crude Ref. 1.73 [1.20–2.48] 0.003 2.56 [1.82–3.61] <0.001 3.13 [2.25–4.37] <0.001 <0.001
Model 1 Ref. 1.14 [0.79–1.65] 0.49 1.62 [1.14–2.30] 0.007 1.78 [1.26–2.53] 0.001 <0.001
Model 2 Ref. 1.12 [0.78–1.62] 0.55 1.57 [1.10–2.24] 0.013 1.72 [1.21–2.44] 0.002 <0.001
Model 3 Ref. 1.17 [0.81–1.70] 0.41 1.62 [1.13–2.32] 0.009 1.83 [1.28–2.62] 0.001 <0.001
Model 4 Ref. 1.18 [0.82–1.72] 0.38 1.64 [1.14–2.34] 0.007 1.81 [1.26–2.59] 0.001 <0.001
Model 5 Ref. 1.20 [0.83–1.75] 0.33 1.63 [1.14–2.34] 0.008 1.80 [1.26–2.59] 0.001 <0.001
Model 6 Ref. 1.16 [0.79–1.68] 0.45 1.49 [1.03–2.17] 0.036 1.55 [1.03–2.32] 0.034 0.023
hsCRP
Participants (n) 1373 1388 1384 1381
Range, mg L1 <0.62 ≥0.62 ≥1.36 ≥3.08
No. of deaths (%) 38 (2.8) 84 (6.1) 119 (8.6) 139 (10.1)
Crude Ref. 2.19 [1.49–3.21] <0.001 3.20 [2.22–4.61] <0.001 3.85 [2.69–5.51] <0.001 <0.001
Model 1 Ref. 1.46 [0.99–2.15] 0.056 1.84 [1.26–2.68] 0.002 2.09 [1.43–3.05] <0.001 0.001
Model 2 Ref. 1.48 [1.01–2.19] 0.047 1.84 [1.26–2.69] 0.002 2.06 [1.41–3.00] <0.001 0.001
Model 3 Ref. 1.48 [1.00–2.19] 0.048 1.86 [1.27–2.73] 0.001 2.05 [1.40–3.01] <0.001 0.002
Model 4 Ref. 1.47 [0.99–2.17] 0.055 1.83 [1.25–2.68] 0.002 1.98 [1.35–2.91] 0.001 0.004
Model 5 Ref. 1.48 [1.00–2.19] 0.049 1.82 [1.24–2.68] 0.002 1.96 [1.33–2.89] 0.001 0.006
Model 6 Ref. 1.43 [0.97–2.12] 0.073 1.71 [1.15–2.53] 0.007 1.71 [1.12–2.61] 0.014 0.13
Hazard ratios were derived from Cox proportional hazards regression models.
Model 1: crude model + age, sex, BMI, alcohol intake (<10g d1 or> 10 g d1) and smoking status (never, former current).
Model 2: model 1 + diabetes, systolic blood pressure, lipid-lowering drugs and anti-hypertensive medications.
Model 3: model 2 + total cholesterol, HDL cholesterol and triglycerides.
Model 4: Model 3 + history of CVD and history of cancer.
Model 5: Model 4 + eGFRcreatinine cystatin C and UAE.
Model 6: Model 5 + hsCRP (for GlycA analyses) + GlycA (for hsCRP analyses).
Triglycerides, UAE and hsCRP were log transformed when used as a continuous variable in the analyses.
BMI, body mass index; CVD, cardiovascular disease; HDL cholesterol, high-density lipoprotein cholesterol; hsCRP, high-
sensitivity C-reactive protein; PREVEND, Prevention of Renal and Vascular End-stage Disease; UAE, urinary albumin
excretion.
aTests of trend across increasing quartiles were conducted by assigning the median for each quartile as its value and
treating this as a continuous variable.>
Values in bold are statistically significant (P<0.05).
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revealed that the positive association of GlycA and
hsCRP with cancer mortality was only present in
men, but not in women. The association of higher
GlycA with increased total cancer mortality was in
part attributable to an increased risk of lung and
gastrointestinal cancer mortality.
GlycA represents a subset of acute-phase reac-
tants, including a1-acid glycoprotein, haptoglobin,
a1-antitrypsin, a1-antichymotrypsin and transfer-
rin [8]. Its composite nature likely has the advan-
tage of giving more stability compared to a single
and more variable marker such as hsCRP [8].
Based on the meta-analysis [11,18–21], individu-
als with the highest GlycA levels were found to have
a 74% greater risk to die from any cause compared
to individuals with the lowest GlycA category.
Consistent with our findings, a1-acid glycoprotein,
one of the major contributors to the GlycA signal,
was found to be associated with all-cause mortality
in two large cohorts in Estonia and Finland [28]. In
line, Ritchie et al. [29] recently showed that of
GlycA’s constituent glycoproteins, a1-antitrypsin
was the strongest predictor for future disease risk
and mortality. Our analyses in the PREVEND study
furthermore showed that hsCRP was also associ-
ated with all-cause mortality. Notably, however,
significance was lost after adjustment for GlycA,
suggesting that the association of GlycA with all-
cause mortality was stronger.
The association of hsCRP with CVD has been firmly
established in numerous studies [30,31]. Although
we did find statistically significant trends of GlycA
and hsCRP with CVD mortality in unadjusted
models, these associations were abolished by con-
trolling for age, sex and lifestyle factors. This may
indicate that elevations in GlycA and hsCRP are
nonspecific responses to environmental stimuli
and may not be related directly or indirectly with
the pathogenesis of cardiovascular mortality. In
line with this, results from Mendelian randomiza-
tion studies indicate that CRP variants do not
independently confer increased CVD risk [32,33].
Moreover, whether CRP should be used to screen
asymptomatic persons is still a matter of debate
[34,35]. Notably, in the PREVEND study, we have
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Relative risk (95% CI) comparing extreme quartiles of GlycA
Fig. 1 Relative risks for mortality comparing extreme quartiles of GlycA in published studies. ANGES: Angiography and
Genes Study; AIM-HIGH trial: Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and
Impact on Global Health Outcomes; CATHGEN, Catheterization Genetics; CI, confidence intervals (bars); JUPITER,
Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin; MESA, Multi-Ethnic
Study of Atherosclerosis; PREVEND, Prevention of Renal and Vascular End-stage Disease; RR, relative risk; WHS, Women’s
health study.
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associated with incident CVD, using a combined
endpoint of CVD morbidity and mortality [9].
Overall, results of the current study, therefore,
suggest that these associations are mainly driven
by CVD morbidity. In our cohort, 24% of all deaths
were attributable to cardiovascular causes, which
is comparable with cardiovascular death rates
from the entire Dutch population in 2016 [36].
This supports the idea that the PREVEND study is
a representative reflection of the general Dutch
population.
The current study showed that GlycA and hsCRP
were positively associated with total cancer mor-
tality in men and not in women. This finding is in
agreement with the results of an earlier meta-
analysis, including six studies comprising a total of
55 721 participants and 3180 deaths due to
cancer, which observed an effect of elevated hsCRP
on cancer-related mortality only in men [31]. The
nonsignificant association in women may be attri-
butable to lower statistical power or heterogeneity
of different types of cancer. In addition, a cross-
sectional study of postmenopausal women using
hormone replacement therapy (HRT) showed
increased CRP levels compared to women not
taking HRT [37]. Comparable results were found
in young adult women using low-dose oral contra-
ceptives [38]. HRT and oral contraceptive use may
cause elevated levels of both GlycA and hsCRP in
women with relatively healthy lifestyles, which
might attenuate the effect on cancer mortality risk.
However, in our study, exclusion of 358 women on
HRT therapy and oral contraceptives did not alter
the results (data not shown). Further studies are
needed to investigate the mechanisms behind the
lack of statistical significance between systemic
low-grade inflammation and cancer mortality in
women. In addition, subgroup analysis results
suggested that GlycA might also be predictive for
lung cancer mortality. A similar observation was
reported by Duprez et al. who found that GlycA was
associated with lung cancer mortality in an anal-
ysis including 107 deaths [11]. Furthermore, in an
exploratory analysis, we showed a significant asso-
ciation between GlycA and gastrointestinal cancer
mortality. Interestingly, results of the WHS showed
that GlycA was associated with colon cancer mor-
tality in initially healthy women [16].
The strengths of our study include analyses of
primary data as well as a meta-analysis of all
available published cohorts on GlycA and all-cause
mortality so far. Furthermore, the PREVEND study
has measurement on comprehensive number of
lifestyle and biological markers that enabled ade-
quate adjustment for potential confounders. On
the other hand, our study also has some limita-
tions to consider. First, our findings were based on
a single baseline measurement of hsCRP and
GlycA. However, the study of Ritchie et al. [39]
showed stable GlycA elevations for periods of up to
a decade. Second, as an observational study, it
does not allow for identification of underlying
causes. Finally, our meta-analysis was based on
study-level data and did not involve individual
participant data, which might give more reliable
risk estimates compared to study-level data.
In conclusion, in this prospective study involving
both men and women, the relative risk for all-cause
mortality increased significantly with each increas-
ing quartile of baseline GlycA level. GlycA and
hsCRP were not independently associated with
cardiovascular mortality in this study. The associ-
ation of GlycA and hsCRP with cancer mortality
appears to be driven by men.
Conflict of interest statement
MAC is an employee of LabCorp.
Data availability statement
The datasets generated during and/or analysed
during the current study are available from the
corresponding author on reasonable request.
Acknowledgments
The GlycA measurements were performed by
LipoScience/LabCorp (Morrisville, North Carolina,
USA) at no cost. The help of prof. H.L. Hillege in the
infrastructure of the PREVEND project is highly
appreciated.
References
1 Kantor ED, Lampe JW, Kratz M, White E. Lifestyle factors and
inflammation: associations by body mass index. PLoS ONE
2013; 8: e67833.
2 Borodulin K, Laatikainen T, Salomaa V, Jousilahti P. Associ-
ations of leisure time physical activity, self-rated physical
fitness, and estimated aerobic fitness with serum C-reactive
proteinamong3,803adults.Atherosclerosis2006;185:381–7.
3 Wannamethee SG, Lowe GD, Shaper AG, Rumley A, Lennon L,
Whincup PH. Associations between cigarette smoking,
pipe/cigar smoking, and smoking cessation, and haemostatic
GlycA and mortality / E. G. Gruppen et al.
12 ª 2019 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine
Journal of Internal Medicine
and inflammatory markers for cardiovascular disease. Eur
Heart J 2005; 26: 1765–73.
4 Ajani UA, Ford ES, Mokdad AH. Dietary fiber and C-reactive
protein: findings from national health and nutrition exami-
nation survey data. J Nutr 2004; 134: 1181–5.
5 Pearson TA, Mensah GA, Alexander RW, et al. Markers of
inflammation and cardiovascular disease: application to clin-
ical and public health practice: a statement for healthcare
professionals from the Centers for Disease Control and
Prevention and the American Heart Association. Circulation
2003; 107: 499–511.
6 Duncan BB, Schmidt MI, Pankow JS, et al. Low-grade
systemic inflammation and the development of type 2 dia-
betes: the atherosclerosis risk in communities study. Diabetes
2003; 52: 1799–805.
7 Coussens LM, Werb Z. Inflammation and cancer. Nature
2002; 420: 860–7.
8 Otvos JD, Shalaurova I, Wolak-Dinsmore J, et al. GlycA: a
composite nuclear magnetic resonance biomarker of systemic
inflammation. Clin Chem 2015; 61: 714–23.
9 Gruppen EG, Riphagen IJ, Connelly MA, Otvos JD, Bakker
SJ, Dullaart RP. GlycA, a pro-inflammatory glycoprotein
biomarker, and incident cardiovascular disease: relationship
with C-reactive protein and renal function. PLoS ONE 2015;
10: e0139057.
10 Dullaart RP, Gruppen EG, Connelly MA, Otvos JD, Lefrandt
JD. GlycA, a biomarker of inflammatory glycoproteins, is
more closely related to the leptin/adiponectin ratio than to
glucose tolerance status. Clin Biochem 2015; 48: 811–4.
11 Duprez DA, Otvos J, Sanchez OA, Mackey RH, Tracy R,
Jacobs Jr DR. Comparison of the predictive value of GlycA
and other biomarkers of inflammation for total death, inci-
dent cardiovascular events, noncardiovascular and non-
cancer inflammatory-related events, and total cancer events.
Clin Chem 2016; 62: 1020–31.
12 Akinkuolie AO, Buring JE, Ridker PM, Mora S. A novel protein
glycan biomarker and future cardiovascular disease events. J
Am Heart Assoc 2014; 3: e001221.
13 Akinkuolie AO, Pradhan AD, Buring JE, Ridker PM, Mora S.
Novel protein glycan side-chain biomarker and risk of inci-
dent type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol
2015; 35: 1544–50.
14 Connelly MA, Gruppen EG, Wolak-Dinsmore J, et al. GlycA, a
marker of acute phase glycoproteins, and the risk of incident
type 2 diabetes mellitus: PREVEND study. Clin Chim Acta
2016; 452: 10–7.
15 Akinkuolie AO, Glynn RJ, Padmanabhan L, Ridker PM, Mora
S. Circulating N-linked glycoprotein side-chain biomarker,
rosuvastatin therapy, and incident cardiovascular disease: an
analysis from the JUPITER trial. J Am Heart Assoc 2016; 5.
https://doi.org/10.1161/JAHA.116.003822
16 Chandler PD, Akinkuolie AO, Tobias DK, et al. Association of
N-linked glycoprotein acetyls and colorectal cancer incidence
and mortality. PLoS ONE 2016; 11: e0165615.
17 Gruppen EG, Connelly MA, Sluiter WJ, Bakker SJ, Dullaart
RP. Higher plasma GlycA, a novel pro-inflammatory glyco-
protein biomarker, is associated with reduced life expectancy:
The PREVEND study. Clin Chim Acta 2018; 488: 7–12.
18 McGarrah RW, Kelly JP, Craig DM, et al. A novel protein
glycan-derived inflammation biomarker independently pre-
dicts cardiovascular disease and modifies the association of
HDL subclasses with mortality. Clin Chem 2017; 63: 288–96.
19 Otvos JD, Guyton JR, Connelly MA, et al. Relations of GlycA
and lipoprotein particle subspecies with cardiovascular
events and mortality: a post hoc analysis of the AIM-HIGH
trial. J Clin Lipidol 2018; 12: 348–55.
20 Kettunen Johannes, Ritchie Scott C, Anufrieva Olga, et al.
Biomarker glycoprotein acetyls is associated with the risk of a
wide spectrum of incident diseases and stratifies mortality
risk in angiography patients. Circulation 2018; 11. https://
doi.org/10.1161/CIRCGEN.118.002234
21 Lawler PR, Akinkuolie AO, Chandler PD, et al. Circulating N-
linked glycoprotein acetyls and longitudinal mortality risk.
Circ Res 2016; 118: 1106–15.
22 Hillege HL, Janssen W, Bak A, et al. Microalbuminuria is
common, also in a nondiabetic, nonhypertensive population,
and an independent indicator of cardiovascular risk factors
and cardiovascular morbidity. J Intern Med 2001; 249: 519–
26.
23 Casparie M, Tiebosch A, Burger G, et al. Pathology databank-
ing and biobanking in The Netherlands, a central role for
PALGA, the nationwide histopathology and cytopathology
data network and archive. Cell Oncol 2007; 29: 19–24.
24 Inker LA, Schmid CH, Tighiouart H, et al. Estimating
glomerular filtration rate from serum creatinine and cystatin
C. N Engl J Med 2012; 367: 20–9.
25 Matyus SP, Braun PJ, Wolak-Dinsmore J, et al. NMR mea-
surement of LDL particle number using the Vantera Clinical
Analyzer. Clin Biochem 2014; 47: 203–10.
26 Corsetti JP, Bakker SJ, Sparks CE, Dullaart RP. Apolipopro-
tein A-II influences apolipoprotein E-linked cardiovascular
disease risk in women with high levels of HDL cholesterol and
C-reactive protein. PLoS ONE 2012; 7: e39110.
27 Selvin S. Statistical Analysis of Epidemiologic Data. Oxford,
UK: Oxford University Press, 2004.
28 Fischer K, Kettunen J, W€urtz P, et al. Biomarker profiling by
nuclear magnetic resonance spectroscopy for the prediction
of all-cause mortality: an observational study of 17,345
persons. PLoS Medicine 2014; 11: e1001606.
29 Ritchie SC, Kettunen J, Brozynska M, et al. Elevated alpha-1
antitrypsin is a major component of GlycA-associated risk for
future morbidity and mortality. bioRxiv 2018.
30 Collaboration Emerging Risk Factors. C-reactive protein
concentration and risk of coronary heart disease, stroke,
and mortality: an individual participant meta-analysis.
Lancet 2010; 375: 132–40.
31 Li Y, Zhong X, Cheng G, et al. Hs-CRP and all-cause,
cardiovascular, and cancer mortality risk: a meta-analysis.
Atherosclerosis 2017; 259: 75–82.
32 Elliott P, Chambers JC, Zhang W, et al. Genetic loci associ-
ated with C-reactive protein levels and risk of coronary heart
disease. JAMA 2009; 302: 37–48.
33 Zacho J, Tybjærg-Hansen A, Jensen JS, Grande P, Sillesen H,
Nordestgaard BG. Genetically elevated C-reactive protein and
ischemic vascular disease. N Engl J Med 2008; 359: 1897–908.
34 Pepys MB. CRP or not CRP? That is the question. Arterioscler
Thromb Vasc Biol 2005; 25: 1091–4.
35 Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive
protein and other circulating markers of inflammation in the
prediction of coronary heart disease. N Engl J Med 2004; 350:
1387–97.
36 Bots M, Buddeke J, Koopman C, Vaartjes I, Visseren F. Hart-
en vaatziekten in nederland 2017. Cijfers of leefstijl, risico-
factoren, ziekte en sterfte, 2017.
GlycA and mortality / E. G. Gruppen et al.
ª 2019 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine 13
Journal of Internal Medicine
37 Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE.
Hormone replacement therapy and increased plasma con-
centration of C-reactive protein. Circulation 1999; 100: 713–
6.
38 Dreon DM, Slavin JL, Phinney SD. Oral contraceptive use and
increased plasma concentration of C-reactive protein. Life Sci
2003; 73: 1245–52.
39 Ritchie SC, W€urtz P, Nath AP, et al. The biomarker GlycA is
associated with chronic inflammation and predicts long-term
risk of severe infection. Cell Syst 2015; 1: 293–301.
Correspondence: Eke G. Gruppen, Department of Nephrology and
Endocrinology, University Medical Center Groningen, University
of Groningen, P.O. Box 30.001, Groningen 9700 RB, The Nether-
lands. (fax: 0503619392; e-mail: e.g.gruppen@umcg.nl).
Supporting Information
Additional Supporting Information may be found in
the online version of this article:
Figure S1. Relative risks for mortality comparing
extreme quartiles of GlycA in published studies.
Table S1. Sex-stratified analyses between hsCRP
and cancer mortality in 5526 participants (380
events) of the PREVEND study.
Table S2. Sex-stratified analyses between GlycA
and cancer mortality in 5526 participants (380
events) of the PREVEND study.
Table S3. Association between GlycA and hsCRP
levels and lung cancer mortality in 5526 partici-
pants (57 events) of the PREVEND study.
Table S4. Association between GlycA and hsCRP
levels and gastrointestinal cancer mortality in
5526 participants (56 events) of the PREVEND
study.
GlycA and mortality / E. G. Gruppen et al.
14 ª 2019 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine
Journal of Internal Medicine
